Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone phosphate
Drug ID BADD_D00624
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
Marketing Status Prescription; Discontinued
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D07802
MeSH ID C004180
PubChem ID 9400
TTD Drug ID D0NA8U
NDC Product Code 0009-5019; 55718-157; 42195-270; 47781-914; 47781-916; 55700-961; 63629-4127; 63629-7850; 67296-0326; 68071-4127; 0054-8183; 46439-8765; 51552-0430; 55718-133; 48102-050; 48102-051; 51407-361; 61919-827; 68788-7142; 70518-2998; 0054-4184; 0054-4186; 49452-2465; 57582-031; 65089-0045; 42195-127; 55289-903; 60219-2043; 60219-2044; 63187-561; 64980-509; 69306-111; 69306-114; 0054-4181; 0054-8175; 71161-138; 79572-012; 82298-111; 43063-266; 63629-3742; 63629-4129; 68071-2321; 68788-7267; 0054-4182; 0054-8176; 52128-170; 50090-0089; 50090-0090; 50090-0091; 63629-7806; 69306-112; 71205-012; 0054-4180; 0054-8174; 51927-1081; 0998-0615; 42195-490; 45865-989; 48102-052; 49999-059; 0023-3348; 55289-582; 55700-854; 0054-4179; 72189-254; 72893-015; 0395-8142; 22552-0039; 55718-156; 42195-721; 48102-047; 48102-049; 61919-269; 70382-204; 0054-3177; 71205-013; 0054-8179; 79043-200; 0121-0907; 55154-4914; 0054-8181; 71879-001; 60722-3013; 15014-211; 42195-121; 42195-151; 60432-466; 63187-383; 67296-1413; 70518-1534; 0054-4183; 0054-8180; 38779-0405; 0121-1814; 42195-149; 42195-221; 50090-0088; 54879-003; 55154-4901; 70518-3050
Synonyms dexamethasone 21-phosphate | dexamethasone phosphate | dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer | dexamethasone sodium phosphate | dexamethasonedisodium phosphate | dexamethasone phosphate disodium salt | Solu- Decadron | Spersadex | Spersadox | dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer | Decadron phosphate | dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C22H30FO8P
CAS Registry Number 312-93-6
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)(O)O)O)C)O)F)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Increased tendency to bruise24.07.06.012; 01.01.03.005; 23.06.01.009--Not Available
Inflammatory bowel disease07.08.01.016--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Large intestine perforation12.02.03.005; 07.04.06.005--
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.004--
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Menstruation irregular21.01.01.005; 05.05.01.008--
Muscle atrophy15.05.03.003; 17.05.03.004--Not Available
Muscle disorder15.05.03.014--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture02.04.02.002; 12.01.11.002--Not Available
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Necrosis ischaemic24.04.02.018--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nitrogen balance negative13.13.01.010--Not Available
Oesophageal candidiasis11.03.03.008; 07.19.06.001--Not Available
Oesophagitis07.08.05.001--
Opportunistic infection11.01.08.007--Not Available
Optic neuritis17.04.05.001; 10.04.10.002; 06.04.08.002--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages